二价COVID-19加强针对刺突特异性T细胞应答的影响
本研究刻画了人类接种二价COVID-19加强针后刺突特异性T细胞应答,评估活化标志物、细胞因子产生及既往感染对不同刺突变异株应答的影响。结果与二价加强针对刺突T细胞应答影响有限相一致,对Omicron BA.4/BA.5变异株与祖先株刺突观察到相似幅度和功能;但加强针对T细胞应答较差或下降的免疫功能正常个体有益,可增加血液中特异性T细胞频率。
要点
- 二价加强针对刺突T细胞应答影响有限,对Omicron BA.4/BA.5与祖先株刺突应答幅度和功能相似。
- 加强针对T细胞应答较差或下降的免疫功能正常个体有益,可增加血液中特异性T细胞频率。
- 研究评估了活化标志物、细胞因子产生及既往COVID-19感染对不同刺突变异株应答的影响。
核心结论
- 二价加强针对刺突T细胞应答影响有限,对Omicron BA.4/BA.5变异株与祖先株刺突观察到相似幅度和功能。
- 加强针对T细胞应答较差或下降的免疫功能正常个体有益,可增加血液中特异性T细胞频率。
研究设计与样本
- 本研究在人类中刻画了接种二价加强针后刺突特异性T细胞应答。
- 研究深入分析了T细胞,评估活化标志物、细胞因子产生及既往COVID-19感染对不同刺突变异株应答的影响。
主要发现
- 总体上,结果与二价加强针对刺突T细胞应答影响有限相一致。
- 对Omicron BA.4/BA.5变异株与祖先株刺突观察到相似幅度和功能。
- 加强针对T细胞应答较差或下降的免疫功能正常个体有益,增加血液中特异性T细胞频率。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The emergence of SARS-CoV-2 variants during the COVID-19 pandemic prompted updates to the original vaccines to improve immunogenicity against novel SARS-CoV-2 variants. Since 2022, vaccination guidelines introduced updated mRNA boosters, starting with a bivalent formulation that included the original and Omicron BA.4/BA.5 spike sequences, which emerged in late 2021. In this study, we characterized the spike-specific T cell response following the bivalent booster vaccination in humans. We performed an in-depth profiling of T cells, assessing activation markers, cytokine production and the impact of previous COVID-19 infection in the response to different spike variants. Overall, our results are consistent with the bivalent booster having a limited influence on spike-T cell responses, with similar magnitude and functionality observed toward the Omicron BA.4/BA.5 variant and the ancestral spike. Nonetheless, the booster proved to be beneficial for immunocompetent individuals with poor or declining T cell responses, increasing the frequency of specific T cells in blood.
引用
- Martínez-Pérez A, Gálvez RI, Grifoni A, et al. Impact of the bivalent COVID-19 booster on spike-specific t cell responses. Vaccine. 2025. PMID: 41242291. doi:10.1016/j.vaccine.2025.127995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。